in vivo News and Research

RSS

New strategy for mRNA nanocarriers using triphenyl phosphonium

Among the vastly different ways of tackling a disease, controlling the genetic expression of cells is undoubtedly one of the most powerful. Over the past few decades, scientists have come up with dozens of innovative strategies that involve using messenger RNA (mRNA) to 'force' cells to build specific proteins. These mRNA-based therapies have recently gained prominence as vaccines against infectious diseases like COVID-19. Additionally, they hold significant potential for treating cancer and genetic disorders.

23 Jul 2024

Research may pave the way for systemic targeted therapy for patients with pseudomyxoma peritonei

Published in Clinical Cancer Research, results of a preclinical study led by investigators of the Vall d'Hebron Institute of Oncology's (VHIO) Stem Cells and Cancer Group, headed by Héctor G. Palmer, pave the way for systemic targeted therapy in patients with pseudomyxoma peritonei, a rare form of cancer with very few therapeutic options available.

19 Jul 2024

Hydrogel implant technology offers new hope for women seeking reversible sterilization and endometriosis treatment

Hydrogel implants for reversible fallopian tube occlusion, providing contraception and preventing endometriosis.

19 Jul 2024

Distinct signaling pathway drives the transformation of epithelial cells into aggressive tumors

A distinct signaling pathway called TNF-α drives the transformation of epithelial cells into aggressive tumor cells.

18 Jul 2024

Novel neutrophil-engineered nanovesicles could transform infectious wound treatment

A recent study has developed nanovesicles (NVs) from activated neutrophils, showcasing their ability to perform molecular debridement and accelerate healing in infectious wounds.

18 Jul 2024

Researchers find a special group of "first responder" cells crucial for triggering blood sugar response

How does our body control blood sugar so precisely? An international research team led by scientists from the Paul Langerhans Institute Dresden (PLID) of the German Center for Diabetes Research brought us a step closer to the answer.

17 Jul 2024

Study highlights the role of RGS16 in glioma progression

Gang Li et al., at Department of Neurosurgery, Qilu Hospital, Shandong University, China, presented a comprehensive study on the role of regulator of G-protein signaling 16 (RGS16) in the progression of glioma, a highly aggressive central nervous system tumor.

17 Jul 2024

Sapio Sciences launches partner program to accelerate research and diagnostics

Sapio Sciences, the science-aware™ lab informatics platform, today announced the Sapio Partner Program.

From Sapio Sciences 17 Jul 2024

Researchers identify ORF6 protein as key to SARS-CoV-2 immune evasion

An article published in the journal Cell describes a study that enabled a group of researchers to discover how SARS-CoV-2 evades the cytotoxic immune response by identifying a protein called ORF6 that is a key factor in this mechanism.

16 Jul 2024

CePA: Novel nanomedicine for alleviating MASH via mTOR repression

Metabolic dysfunction-associated steatohepatitis (MASH) is one of the most common chronic liver diseases, primarily caused by metabolic disorders and systemic inflammatory responses.

16 Jul 2024

New approaches for repairing the function of mutated proteins that cause stroke

Cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy (CARASIL) is a rare, severe, and deadly genetic disorder characterized by damage to small blood vessels in the brain and which triggers strokes.

16 Jul 2024

ARPA-H funding boosts Wyss Institute's RNA therapeutic project

With the award for up to $27 million from the Advanced Research Projects Agency for Health (ARPA-H), a collaborative research project at the Wyss Institute for Biologically Inspired Engineering at Harvard University will advance a disease-agnostic novel RNA therapeutic with the potential to treat diverse diseases, and to be effectively and rapidly deployable.

15 Jul 2024

Mogrify appoints Dr. Jonathan Appleby as Chief Scientific Officer

Strategic hire bolsters executive leadership team as Company progresses multiple therapeutic programs toward and into clinical development.

From Mogrify 15 Jul 2024

One-time prime editing targets common genetic cause of cystic fibrosis

Researchers optimized prime editing for the efficient correction of the cystic fibrosis transmembrane conductance regulator F508del mutation in human airway epithelial cells, achieving high correction efficiencies and functional restoration with minimal off-target effects.

15 Jul 2024

Twincretin drug Tirzepatide shows unmatched efficacy in weight loss and diabetes management

Tirzepatide, a novel twincretin drug, significantly improves weight loss and glycemic control in obese and type 2 diabetes patients, outperforming traditional treatments in clinical trials.

15 Jul 2024

New brain targets for GLP1-based obesity drugs may reduce weight without nausea

Researchers identified distinct hindbrain GLP1R neurons driving satiety and aversion, offering new targets for effective, side-effect-free obesity treatments.

14 Jul 2024

Antibody-drug conjugate shows preclinical efficacy

A new editorial paper was published in Oncoscience (Volume 11) on May 20, 2024, entitled, "Entering the golden age for antibody-drug conjugates in gynecologic cancer."

13 Jul 2024

Study identifies RFC4 as key player in nasopharyngeal carcinoma

Lichuan Wu et al., at Medical College of Guangxi University, China, presented a comprehensive study on the role of replication factor C subunit 4 (RFC4) in nasopharyngeal carcinoma (NPC), a type of epithelial cancer commonly associated with Epstein-Barr virus infection.

12 Jul 2024

Novel DNA aptamers of melanopsin developed to regulate circadian rhythm

DNA aptamers of melanopsin that regulate the clock hands of biological rhythms were developed by the Toyohashi University of Technology and the National Institute of Advanced Industrial Science and Technology (AIST) group.

12 Jul 2024

Accelerate Your Research: Dispen3D Harnesses the Power of 3D Models

Dispen3D is setting new standards in single-cell biology, enabling researchers to conduct high-precision experiments that drive advancements in drug discovery, personalized medicine, and regenerative therapies.

From SEED Biosciences 12 Jul 2024